tbuckley/cabot-search huggingface dataset:
Establishment of a Spontaneous Stromal Microenvironment from Cord Blood Supports Human Dynamic Erythropoietic Temporal Maturation in Long-Term Serum- and Cytokine-Free 3D Cultures and Reveals a Distinct CD44hi Population
Authors: Susana Brito Dos Santos, Athanasios Mantalaris, Nicki Panoskaltsis
Journal: Blood (2019)
Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe
Authors: Xilian Bai, Ray Borrow, Suzana Bukovski, Dominique A. Caugant, Davor Culic, Snezana Delic, Ener Cagri Dinleyici, Medeia Eloshvili, Tímea Erdősi, Jelena Galajeva, Pavla Křížová, Jay Lucidarme, Konstantin Mironov, Zuridin Nurmatov, Marina Pana, Erkin Rahimov, Larisa Savrasova, Anna Skoczyńska, Vinny Smith, Muhamed-Kheir Taha, Leonid Titov, Julio Vázquez, Lyazzat Yeraliyeva
Journal: Journal of Infection (2019)

The Global Meningococcal Initiative (GMI) aims to prevent invasive meningococcal disease (IMD) worldwide through education, research and cooperation. In March 2019, a GMI meeting was held with a multidisciplinary group of experts and representatives from countries within Eastern Europe. Across the countries represented, IMD surveillance is largely in place, with incidence declining in recent decades and now generally at <1 case per 100,000 persons per year. Predominating serogroups are B and C, followed by A, and cases attributable to serogroups W, X and Y are emerging. Available vaccines differ between countries, are generally not included in immunization programs and provided to high-risk groups only. Available vaccines include both conjugate and polysaccharide vaccines; however, current data and GMI recommendations advocate the use of conjugate vaccines, where possible, due to the ability to interrupt the acquisition of carriage. Ongoing carriage studies are expected to inform vaccine effectiveness and immunization schedules. Additionally, IMD prevention and control should be guided by monitoring outbreak progression and the emergence and international spread of strains and antibiotic resistance through use of genomic analyses and implementation of World Health Organization initiatives. Protection of high-risk groups (such as those with complement deficiencies, laboratory workers, migrants and refugees) is recommended.
CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
Authors: Delong Liu
Journal: Journal of Hematology & Oncology (2019)

New advances in the design and manufacture of monoclonal antibodies, bispecific T cell engagers, and antibody-drug conjugates make the antibody-directed agents more powerful with less toxicities. Small molecule inhibitors are routinely used now as oral targeted agents for multiple cancers. The discoveries of PD1 and PD-L1 as negative immune checkpoints for T cells have led to the revolution of modern cancer immunotherapy. Multiple agents targeting PD1, PD-L1, or CTLA-4 are widely applied as immune checkpoint inhibitors (ICIs) which alleviate the suppression of immune regulatory machineries and lead to immunoablation of once highly refractory cancers such as stage IV lung cancer. Tisagenlecleucel and axicabtagene ciloleucel are the two approved CD19-targeted chimeric antigen receptor (CAR) T cell products. Several CAR-T cell platforms targeting B cell maturation antigen (BCMA) are under active clinical trials for refractory and/or relapsed multiple myeloma. Still more targets such as CLL-1, EGFR, NKG2D and mesothelin are being directed in CAR-T cell trials for leukemia and solid tumors. Increasing numbers of novel agents are being studied to target cancer-intrinsic oncogenic pathways as well as immune checkpoints. One such an example is targeting CD47 on macrophages which represents a "do-not-eat-me" immune checkpoint. Fueling the current excitement of cancer medicine includes also TCR- T cells, TCR-like antibodies, cancer vaccines and oncolytic viruses.
ILC2s are the predominant source of intestinal ILC-derived IL-10
Authors: Jennifer K. Bando, Susan Gilfillan, Blanda Di Luccia, José L. Fachi, Cristiane Sécca, Marina Cella, Marco Colonna
Journal: The Journal of Experimental Medicine (2019)

Although innate lymphoid cells (ILCs) functionally analogous to T helper type 1 (Th1), Th2, and Th17 cells are well characterized, an ILC subset strictly equivalent to IL-10-secreting regulatory T cells has only recently been proposed. Here, we report the absence of an intestinal regulatory ILC population distinct from group 1 ILCs (ILC1s), ILC2s, and ILC3s in (1) mice bred in our animal facility; (2) mice from The Jackson Laboratory, Taconic Biosciences, and Charles River Laboratories; and (3) mice subjected to intestinal inflammation. Instead, a low percentage of intestinal ILC2s produced IL-10 at steady state. A screen for putative IL-10 elicitors revealed that IL-2, IL-4, IL-27, IL-10, and neuromedin U (NMU) increased IL-10 production in activated intestinal ILC2s, while TL1A suppressed IL-10 production. Secreted IL-10 further induced IL-10 production in ILC2s through a positive feedback loop. In summary, ILC2s provide an inducible source of IL-10 in the gastrointestinal tract, whereas ILCregs are not a generalizable immune cell population in mice.
The DLBCL90 Double-Hit Gene Expression Signature Is Not Associated with Inferior Survival in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma Treated with Dose-Intensive Immunochemotherapy
Authors: Kathrine T. Isaksen, Klaus Beiske, Erlend B. Smeland, Judit Jørgensen, Marianne Brodtkorb, June Helen Myklebust, Mats Jerkeman, Leo Meriranta, Marja-Liisa Karjalainen-Lindsberg, Sirpa Leppa, David W. Scott, Harald Holte, Yngvild Nuvin Blaker
Journal: Blood (2019)
Cyclic Nucleotide Signaling: A Second Messenger of Death
Authors: Nina Molin Høyland-Kroghsbo
Journal: Cell Host & Microbe (2019)

All life forms rely on defenses to fight off viruses that prey on them. Intriguingly, bacteria often develop the blueprints for these. Recently published in Nature, Cohen et al. (2019) uncover a widespread bacterial anti-viral defense system, which may be the evolutionary precursor to the metazoan cGAS-STING immune pathway.
Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update
Authors: Peter M. Voorhees, Jonathan L. Kaufman, Jacob P. Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca W. Silbermann, Luciano J. Costa, Larry D. Anderson, Nitya Nathwani, Nina D. Shah, Yvonne A. Efebera, Caitlin L. Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Sean Murphy, Yana Lutska, Huiling Pei, Jon Ukropec, Jessica Vermeulen, Carla de Boer, Daniela Hoehn, Thomas S. Lin, Paul G. Richardson
Journal: Blood (2019)
EXTH-65. PLASMA AND CEREBROSPINAL FLUID PHARMACOKINETICS COMPARISON OF BRAF AND MEK INHIBITORS FOLLOWING SINGLE AND EXTENDED ADMINISTRATION IN A PRE-CLINICAL NON-HUMAN PRIMATE MODEL
Authors: Cynthia Lester McCully, Andrea Gross, Rafael Cruz Garcia, Priya Shankarappa, Arman Odabas, Louis Rodgers, Cody Peer, William Figg, Brigitte Widemann, Katherine Warren
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Aberrations in the MAPK signaling pathway are present in adult and pediatric CNS tumors. The BRAF and MEK inhibitors Dabrafenib, Vemurafenib, Selumetinib and Trametinib, alone or in combination, have demonstrated clinical efficacy. However, minimal CSF penetration has been demonstrated in pre-clinical models with single dose administration. CSF penetration of these agents was compared following single and extended oral administration in a nonhuman CSF Lateral Reservoir model to determine if CSF penetration increases at steady state. METHODS Agents were administered orally, to each subject (n=9), in single or multiple doses, as serial single agent studies, with washout periods between studies. The following dosages (Human equivalent dose HED) were utilized in the studies: Single Dosage-Selumetinib 2.5 mg/kg (50.0 mg/m2), Dabrafenib 8.0 mg/kg (160 mg/m2), Vemurafenib 26 mg/kg (520 mg/m2), Trametinib 0.06 and 0.12 mg/kg (1.2 and 2.4 mg/m2). Extended dosages-Selumetinib 2.5 mg/kg BID x 3 days (50.0 mg/m2), Dabrafenib 4.0 mg/kg BID x 2 days (160 mg/m2/day), Vemurafenib 26 mg/kg BID x 3 days (520 mg/m2), Trametinib 0.05 mg/kg x 10 days BID (1.0mg/m2). Paired serial plasma and CSF samples were collected. Agents were quantified by uHPLC-MS/MS. Pharmacokinetic parameters were calculated via noncompartmental methods. Plasma exposure reported as Area Under the Curve (AUC) and CSF penetration as ratio of CSF:plasma AUC. Statistical significance determined by t-test. RESULTS Single administration AUCinf/D (hr*ng/ml/mg) vs. extended administration AUCtau/D (hr*ng/ml/mg) for each agent: Vemurafenib-Plasma 30.9–351.4 vs.29.2–379.7, CSF-non-quantifiable; Dabrafenib-Plasma 29.3–102.6 vs.3.4–58.2, CSF-0.12–0.54 vs 0.04–0.19, % CSF:Plasma-0.3–0.84 vs.0.32–1.3; Trametinib-Plasma AUC indeterminable, CSF-non-quantifiable; Selumetinib-Plasma 69.8–133.0 vs.26.5–81.2; CSF-AUC indeterminable vs. 0.37–0.86, % CSF:Plasma-Indeterminable vs. 0.78–1.4. T-test: A downward trend in Dabrafenib and Selumetinib plasma AUC and a marked upward trend in Selumetinib CSF AUC. CONCLUSIONS With the exception of Selumetinib, the CSF exposure of BRAF and MEK inhibitors studied did not markedly increase following extended dosing.
Contrast medium-associated renal dysfunction in patients with cirrhosis
Authors: Mónica Guevara, Gloria Fernández–Esparrach, Pere Ginès
Journal: Hepatology (2004)

Reply: We appreciate the comments of Huo et al. related to our recent study in which we investigated the effect of contrast media on renal function in patients with cirrhosis.1 The main finding of our study was that the administration of contrast media was not associated with adverse effects on renal function in patients with cirrhosis; thus suggesting that cirrhosis is not a risk factor for contrast media–induced nephrotoxicity. Huo et al. are not in agreement with our conclusion. The main reason for the disagreement comes from the results of a recent study in which these authors observed a 6.6% incidence of acute renal failure in a large series of patients with cirrhosis and hepatocellular carcinoma treated with transarterial chemoembolization (TAE).2 However, in our opinion, TAE is not a good model to assess changes in renal failure due to contrast media. In fact, TAE may be associated with a number of complications that can result in acute renal failure, such as postembolization syndrome, bacterial infections, ischemic hepatitis, and liver failure. Therefore, the conclusion that changes in renal failure in patients treated with TAE are due to the contrast media is not legitimate. The approach used in our study to evaluate nephrotoxicity due to contrast media (i.e., to assess renal function after administration of contrast media for diagnostic radiological procedures) seems to be the best approach possible, because renal function is not affected by confounding factors. In fact, this approach has been used for years in studies assessing contrast media–induced nephrotoxicity.3-5 Mónica Guevara*, Gloria Fernández-Esparrach*, Pere Ginès*, * Hospital Clinic — Liver Unit, Barcelona, Spain.
SURG-33. IMMUNO-STIMULATION THROUGH SURGICALLY ADMINISTERED MECHANICAL HIGH INTENSITY FOCUSED ULTRASOUND
Authors: James Wang, Chin-Hsin Huang, Oscar Echeagaray, Siamak Amirfakhri, Sarah Blair, William Trogler, Andrew Kummel, Clark Chen
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION While immunotherapy through anti-PD1 checkpoint inhibition has demonstrated impressive clinical efficacy against a number of tumor types, its application has been ineffective against glioblastomas. METHODS We wished to determine whether high intensity focused ultrasound (HIFU) augment the efficacy of anti-PD1 checkpoint inhibition against glioblastomas. HIFU can be surgically administered through low-duty cycle to induce subcellular fragmentation without causing temperature elevation (termed mechanical HIFU). Alternatively, HIFU delivered through high duty cycle can induce foci of temperature elevation and thermal ablation (termed thermal HIFU). We tested the impact of mechanical and thermal HIFU on the anti-glioblastoma effects of the immune checkpoint inhibitor, ipililumab. RESULTS In an in vivomurine glioblastoma model, sites targeted by mechanical HIFU exhibited a 10–100 fold increase in accumulation in tumor infiltrating lymphocytes and interferon-γ (IFN-γ) in the presence of PD-1 blockade. At least 75% of mice engrafted with glioblastomas achieved remission when treated with mechanical HIFU and PD-1 blockade. In contrast, none of the mice treated with single therapies achieved durable remission. Likelihood of remission correlated with the abundance of tumor infiltrating lymphocytes (p&lt; 0.001) and IFN- γ levels (p=0.001). The synergy observed between mechanical HIFU and PD-1 blockade was not seen when combining thermal HIFU and PD-1 blockade, suggesting thermal protein denaturation is prohibitive to immune-stimulatory effects of HIFU. CONCLUSION Mechanical HIFU, but not thermal HIFU, augments the anti-glioblastoma effects of PD-1 blockade. Our findings inform the utility of HIFU as an immune-adjuvant in glioblastoma therapy that can be surgically administered.
Cancer of the head and neck
Authors: M. N. Maisey, E. B. Chevretton
Journal: Clinical Nuclear Medicine (1998)

Cancer of the head and neck is relatively uncommon in Western countries, representing about 5% of all malignant tumours. However, it is extremely common in India and South-East Asia where oral cavity cancer represents 35% of all cancer cases [1,2]. Men are three times more likely than women to develop this form of cancer, with a peak incidence over the age of 50. Risk factors include tobacco and alcohol consumption (these have a synergistic effect), dietary factors, viruses, and exposure to chemicals and fumes. When treating head and neck cancer improved results are achieved when patients are treated in specialized centres with experienced multi-disciplinary teams including head and neck surgeons, radiotherapists and medical oncologists [3]. On account of the site of the tumours, treatment is directed at maintaining both the form and the function of the head and neck structures as well as eradicating the disease.
Modeling Effective AML Therapies - Comparative Anti-Leukemic Synergy of BCL2 and MCL1 Inhibition Combined and with Chemotherapy
Authors: Eric O'Brien, Brett VanCauwenbergh, Jackson Alexander, Mitali Basu, Mark Wunderlich, Mayur Sarangdhar, Benjamin Mizukawa, John P Perentesis
Journal: Blood (2019)
Optimized functional and structural design of dual-target LMRAP, a bifunctional fusion protein with a 25-amino-acid antitumor peptide and GnRH Fc fragment
Authors: Meng Li, Hanmei Xu, Junzhi Wang
Journal: Acta Pharmaceutica Sinica B (2019)

To develop fusion protein of a GnRH Fc fragment and the integrin targeting AP25 antitumor peptide for GnRH receptor-expressing cancer therapy. The LMRAP fusion protein was constructed. A transwell invasion assay was performed. The gene mRNA and protein levels of GnRHR-I, α5β1, and αvβ3 in different cancer cell lines were assessed. Cell proliferation was measured using a cell counting kit-8. An antagonist assay was performed on GnRH receptors. Anti-tumor activity was evaluated with a mouse xenograft tumor model. Immunohistochemistry (IHC) was applied to detect CD31 and CD34 expressions. Pharmacokinetic characteristics were determined with an indirect competition ELISA. The developed bifunctional fusion protein LMRAP not only inhibited HUVEC invasion, but also inhibited proliferation of GnRHR-I, α5β1, and αvβ3 high expression cancer cells. The IC50 for LMRAP in the GnRH receptor was 6.235 × 10-4 mol/L. LMRAP significantly inhibited human prostate cancer cell line 22RV1 proliferation in vivo and in vitro. LMRAP significantly inhibited CD31 and CD34 expressions. The elimination half-life of the fusion protein LMRAP was 33 h in rats. The fusion protein made of a GnRH Fc fragment and the integrin targeting AP25 peptide retained the bifunctional biological activity of GnRHR blocking, angiogenesis inhibition, prolonged half-life and good tolerance.
Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis
Authors: Pui Y Lee, Grant S Schulert, Scott W Canna, Yuelong Huang, Jacob Sundel, Ying Li, Kacie J Hoyt, Rachel B Blaustein, Alexandra Wactor, Thuy Do, Olha Halyabar, Margaret H Chang, Fatma Dedeoglu, Siobhan M Case, Esra Meidan, Mindy S Lo, Robert P Sundel, Edward T Richardson, Jane W Newburger, Michael S Hershfield, Mary Beth Son, Lauren A Henderson, Peter A Nigrovic
Journal: Annals of the Rheumatic Diseases (2019)

Macrophage activation syndrome (MAS) is a life-threatening complication of systemic juvenile idiopathic arthritis (sJIA) characterised by a vicious cycle of immune amplification that can culminate in overwhelming inflammation and multiorgan failure. The clinical features of MAS overlap with those of active sJIA, complicating early diagnosis and treatment. We evaluated adenosine deaminase 2 (ADA2), a protein of unknown function released principally by monocytes and macrophages, as a novel biomarker of MAS.We established age-based normal ranges of peripheral blood ADA2 activity in 324 healthy children and adults. We compared these ranges with 173 children with inflammatory and immune-mediated diseases, including systemic and non-systemic JIA, Kawasaki disease, paediatric systemic lupus erythematosus and juvenile dermatomyositis.ADA2 elevation beyond the upper limit of normal in children was largely restricted to sJIA with concomitant MAS, a finding confirmed in a validation cohort of sJIA patients with inactive disease, active sJIA without MAS or sJIA with MAS. ADA2 activity strongly correlated with MAS biomarkers including ferritin, interleukin (IL)-18 and the interferon (IFN)-γ-inducible chemokine CXCL9 but displayed minimal association with the inflammatory markers C reactive protein and erythrocyte sedimentation rate. Correspondingly, ADA2 paralleled disease activity based on serial measurements in patients with recurrent MAS episodes. IL-18 and IFN-γ elicited ADA2 production by peripheral blood mononuclear cells, and ADA2 was abundant in MAS haemophagocytes.These findings collectively identify the utility of plasma ADA2 activity as a biomarker of MAS and lend further support to a pivotal role of macrophage activation in this condition.
A prospective multi-center quality improvement initiative (NINJA) indicates a reduction in nephrotoxic acute kidney injury in hospitalized children
Authors: Stuart L. Goldstein, Devesh Dahale, Eric S. Kirkendall, Theresa Mottes, Heather Kaplan, Stephen Muething, David J. Askenazi, Traci Henderson, Lynn Dill, Michael J.G. Somers, Jessica Kerr, Jennifer Gilarde, Joshua Zaritsky, Valerie Bica, Patrick D. Brophy, Jason Misurac, Richard Hackbarth, Julia Steinke, Joann Mooney, Sara Ogrin, Vimal Chadha, Bradley Warady, Richard Ogden, Wendy Hoebing, Jordan Symons, Karyn Yonekawa, Shina Menon, Lisa Abrams, Scott Sutherland, Patricia Weng, Fang Zhang, Kathleen Walsh
Journal: Kidney International (2019)
EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia (AML)
Authors: Marius Bill, Aparna Pathmanathan, Malith Karunasiri, Changxian Shen, Matthew Burke, Parvathi Ranganathan, Dimitrios Papaioannou, Nina C. Zitzer, Katiri Snyder, Allison LaRocco, Allison Walker, Zachary Brannan, Ansel P. Nalin, Aharon G. Freud, Mikhail Dikov, Xiaoli Zhang, Clara D. Bloomfield, Ramiro Garzon, Adrienne M. Dorrance
Journal: Blood (2019)
QOLP-19. A NEW MODEL OF CARE FOR PATIENTS WITH CENTRAL NERVOUS SYSTEM CANCERS
Authors: Kathryn Nevel, Franchesca Konig, Mary Elizabeth Davis, Anna Skakodub, Maryann Sibilla, Mabel Harrison, Gayle Rawlins-Peters, Dominique Jean-Charles, Anastasia Zankowsky, Jody Gilman, Brian Kelly, Anne Reiner, Stephanie Zavolas, Hannah Goldman, Eli Diamond, Alan Carver, Lisa Ruppert, Lisa DeAngelis, Elena Pentsova
Journal: Neuro-Oncology (2019)

Abstract Patients (pts) with primary or metastatic central nervous system (CNS) cancers often have multiple physical, psychosocial, and spiritual needs. Neurological impairments can transform relationship dynamics with caregivers. These issues are difficult to address within a single outpatient oncology clinic. The Neurological Multidisciplinary Care Clinic (MdCC) at Memorial Sloan Kettering Cancer Center was a pilot study from 08/2017 to 04/2019 to foster a new model of care for complex pts with CNS cancers to identify and address their needs. The MdCC team: a neurologist, nurse, physiatrist (RM), physical therapist, social worker (SW), case manager (CM), dietitian (RD), and chaplain saw each pt/caregiver during a 3-hour visit. Since 11/2017 participants completed validated surveys on unmet needs, financial strain, and home equipment prior to their visit and satisfaction surveys afterward. Descriptive statistics were used to analyze results. Seventy-eight pts were seen: 39 were female, median age 59. Of these 78 pts, 65 had primary CNS cancers; predominantly glioblastoma (52%) and high-grade glioma (29%). Over 60% had never seen a SW, CM, RD, or physiatrist prior to MdCC. Seventy-six pts (97%) received symptom management recommendations. Prognosis/coping with cancer was discussed with 72 (92%) which increased signed health care proxy forms by 17% and DNR orders by 6% at time or within a month post MdCC. New/updated physical therapy was ordered for 48 pts (61%), orthotics for 8 (10%), and new equipment for 12 (15%). 25 pts (32%) continued following with physiatrists. Forty-eight pts completed a satisfaction survey; of these, 96% were highly satisfied, and would recommend MdCC to others. Pts’/caregivers’ unmet needs were effectively identified and addressed in this new model, The presence of these providers at time of MdCC allows for real time assessment of pts’/caregivers’, their support system, multidisciplinary team collaboration, planning, coordination of community services and implementation of a safe patient centered plan of care.
Acid Drinks and Sulphonamide Therapy
Authors: C. W. M. Whitty
Journal: BMJ (1947)

exertion such as digging or rpowing a rough lawn with an old lawn-mower.The abdominal wall felt icy to the touch, and aftersuch exertion I would have an acute attack as described.It could not be put down to icy water as we had no refrigerator and usually the water remained tepid after boiling.Stools were negative.Apart from these acute attacks I normally had three or four loose stools daily during the hot weather.I eventually found that a " belly pad " consisting of about a square foot of woollen vest, lined on the inside with an old piece of " lock-knit " cotton material, tied round the neck and waist, was almost specific.The Chinese (Hakka) people dress their small children in a "belly pad " in the hot weather.-Iam, etc., Leyburm, Yorks.
Value of Flow Cytometry for MRD-Based Relapse Prediction in B-Cell Precursor Acute Lymphoblastic Leukemia in a Multi-Center Setting
Authors: Signe Modvig, Hans Madsen, Helene Hallböök, Sanna M. Siitonen, Liv T. N. Osnes, Susanne Rosthøj, Anne Tierens, Vesa Juvonen, Helen Vålerhaugen, Magnus Hultdin, Mats Ehinger, Anna Porwit, Reda Matuzeviciene, Mindaugas Stoskus, M Marincevic, Aili Lilleorg, Mervi Taskinen, Nina Toft, Ólafur Gísli Jónsson, Kaie Pruunsild, Goda Elizabeta Vaitkeviciene, Kim Vettenranta, Bendik Lund, Jonas Abrahamsson, Kjeld Schmiegelow, Hanne Vibeke Marquart
Journal: Blood (2019)
Genetic Characteristics and Clinical Outcomes of T-Cell Acute Lymphoblastic Leukemia; Myeloid-Suppressive Therapeutic Approach Based on Allogeneic Hematopoietic Cell Transplantation May Benefit in Early T-Cell Precursor Acute Lymphoblastic Leukemia
Authors: Jae-Ho Yoon, Han Bi Lee, Gi June Min, Sung-Soo Park, Silvia Park, Byung Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Jong Wook Lee, Seok Lee
Journal: Blood (2019)